Related references
Note: Only part of the references are listed.Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
Ralph A. DeFronzo et al.
DIABETES CARE (2010)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Antonio Cervera et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
Sherwyn L. Schwartz et al.
CLINICAL THERAPEUTICS (2008)
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
Ralph A. DeFronzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Improvement of glycemic control in subjects with poorly controlled type 2 diabetes - Comparison of two treatment algorithms using insulin glargine
M Davies et al.
DIABETES CARE (2005)
Initiating insulin therapy in type 2 diabetes - A comparison of biphasic and basal insulin analogs
P Raskin et al.
DIABETES CARE (2005)
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
KB Degn et al.
DIABETES (2004)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
The treat-to-target trial - Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
MC Riddle et al.
DIABETES CARE (2003)
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
A Flint et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
DG Parkes et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Share Paper
